Verily Life Sciences Announces $800 Million Investment by Temasek

January 26, 2017

S&C represents Verily Life Sciences, an Alphabet company, in its partnership with Temasek, under which Temasek will invest $800 million in Verily in exchange for a minority stake in the company.

The S&C team on the transaction was led by Alison Ressler, along with Jason Anderson and Anel Loubser. Marc Treviño and Jeannette Braun advised on executive compensation and benefits matters, Nader Mousavi and Rachel Yu advised on intellectual property matters, and Andrew Mason and Alexander Apostolopoulos advised on tax matters.